Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.
A1, Apolipoprotein A1
A2M, alpha2-macroglobulin
ALT, alanine aminotransferase
Apolipoprotein A1
COVID-19
Dpi, days after infection
GGT, gamma glutamyl transpeptidase
HDL-C, high-density lipoprotein cholesterol
HP, haptoglobin
Haptoglobin
ICU, intensive care unit
NHP, non-human primate model
Nonhuman Primate Model
SAA, serum amyloid A
Journal
Gastro hep advances
ISSN: 2772-5723
Titre abrégé: Gastro Hep Adv
Pays: Netherlands
ID NLM: 9918350485906676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
11
2021
accepted:
29
12
2021
pubmed:
18
2
2022
medline:
18
2
2022
entrez:
17
2
2022
Statut:
ppublish
Résumé
Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are associated with the spread and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We have constructed and validated a multivariable risk calculator (A1HPV6) integrating A1, HP, alpha2-macroglobulin, and gamma glutamyl transferase to improve the performances of virological biomarkers. In a prospective observational study of hospitalized patients with nonsevere SARS-CoV-2 infection, A1HPV6 was constructed in 127 patients and validated in 116. The specificity was assessed in 7482 controls representing the general population. The primary diagnostic endpoint was the area under the receiver operating characteristic curve in patients with positive SARS-CoV-2 PCR. The primary prognostic endpoint was the age-and sex-adjusted risk of A1HPV6 to predict patients with WHO-stage > 4 (W > 4) severity. We assessed the kinetics of the A1HPV6 components in a nonhuman primate model (NHP), from baseline to 7 days (D7) after SARS-CoV-2 infection. The area under the receiver operating characteristic curve for A1HPV6 was 0.99 (95% CI 0.97-0.99) in the validation subset, which was not significantly different from that in the construction subset, 0.99 (0.99-0.99; These results validate the diagnostic and prognostic performances of A1HPV6. Similar kinetics of apolipoprotein A1, HP, and alpha-2-macroglobulin were observed in the NHP model. ClinicalTrials.gov number, NCT01927133.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are associated with the spread and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We have constructed and validated a multivariable risk calculator (A1HPV6) integrating A1, HP, alpha2-macroglobulin, and gamma glutamyl transferase to improve the performances of virological biomarkers.
METHODS
METHODS
In a prospective observational study of hospitalized patients with nonsevere SARS-CoV-2 infection, A1HPV6 was constructed in 127 patients and validated in 116. The specificity was assessed in 7482 controls representing the general population. The primary diagnostic endpoint was the area under the receiver operating characteristic curve in patients with positive SARS-CoV-2 PCR. The primary prognostic endpoint was the age-and sex-adjusted risk of A1HPV6 to predict patients with WHO-stage > 4 (W > 4) severity. We assessed the kinetics of the A1HPV6 components in a nonhuman primate model (NHP), from baseline to 7 days (D7) after SARS-CoV-2 infection.
RESULTS
RESULTS
The area under the receiver operating characteristic curve for A1HPV6 was 0.99 (95% CI 0.97-0.99) in the validation subset, which was not significantly different from that in the construction subset, 0.99 (0.99-0.99;
CONCLUSION
CONCLUSIONS
These results validate the diagnostic and prognostic performances of A1HPV6. Similar kinetics of apolipoprotein A1, HP, and alpha-2-macroglobulin were observed in the NHP model. ClinicalTrials.gov number, NCT01927133.
Identifiants
pubmed: 35174366
doi: 10.1016/j.gastha.2021.12.009
pii: S2772-5723(22)00006-1
pmc: PMC8818442
doi:
Banques de données
ClinicalTrials.gov
['NCT01927133']
Types de publication
Journal Article
Langues
eng
Pagination
393-402Informations de copyright
© 2022 The Authors.
Références
Am J Clin Exp Immunol. 2012 May 30;1(1):33-48
pubmed: 23885313
J Thromb Haemost. 2021 Feb;19(2):351-354
pubmed: 33230947
EMBO Mol Med. 2021 Aug 9;13(8):e14167
pubmed: 34232570
BMC Gastroenterol. 2010 Apr 22;10:40
pubmed: 20412588
Front Mol Biosci. 2021 Feb 22;8:632290
pubmed: 33693030
Front Cardiovasc Med. 2020 Dec 04;7:584987
pubmed: 33344516
Dig Dis Sci. 1994 Nov;39(11):2426-32
pubmed: 7525168
Arterioscler Thromb Vasc Biol. 2020 Jan;40(1):267-278
pubmed: 31694394
FASEB J. 2020 Aug;34(8):9843-9853
pubmed: 32588493
Eur Heart J. 2018 Apr 7;39(14):1181-1190
pubmed: 29228167
Nat Commun. 2021 Oct 20;12(1):6097
pubmed: 34671037
Curr Atheroscler Rep. 2021 Feb 16;23(3):11
pubmed: 33591433
J Clin Lab Anal. 2021 Aug;35(8):e23911
pubmed: 34260764
J Exp Med. 1976 Jul 1;144(1):1-9
pubmed: 58955
Biol Chem. 2003 Dec;384(12):1593-6
pubmed: 14719801
PLoS One. 2020 Sep 24;15(9):e0239573
pubmed: 32970772
Prev Med Rep. 2021 Sep;23:101461
pubmed: 34178592
BMJ Open. 2020 Aug 5;10(8):e039856
pubmed: 32759252
J Hepatol. 2012 Sep;57(3):541-8
pubmed: 22612998
PLoS One. 2021 Apr 1;16(4):e0248602
pubmed: 33793566
Sci Rep. 2021 Jan 27;11(1):2291
pubmed: 33504824
Nat Metab. 2020 Dec;2(12):1391-1400
pubmed: 33244168
BMC Gastroenterol. 2011 Apr 14;11:39
pubmed: 21492460
PLoS One. 2020 Nov 20;15(11):e0242306
pubmed: 33216772
Adv Exp Med Biol. 2021;1318:109-118
pubmed: 33973175
Comput Struct Biotechnol J. 2021;19:2833-2850
pubmed: 34025952
PLoS Comput Biol. 2021 Mar 17;17(3):e1008785
pubmed: 33730053
Gut Microbes. 2021 Jan-Dec;13(1):1-19
pubmed: 33685349
J Hepatol. 2021 Oct;75(4):848-855
pubmed: 33992699
J Proteome Res. 2020 Nov 6;19(11):4219-4232
pubmed: 32657586
Cell Syst. 2021 Aug 18;12(8):780-794.e7
pubmed: 34139154
Sci Rep. 2021 Aug 26;11(1):17225
pubmed: 34446802